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R()WIN 55,212-2 is a synthetic cannabinoid that controls dis-
ease progression in models of multiple sclerosis. This is associated
with its ability to reduce migration of leukocytes into the central
nervous system. Because leukocyte migration is dependent on
induction of adhesionmolecules and chemokines by pro-inflamma-
tory cytokines, we examined the effects of R()WIN 55,212-2 on
their expression. Using 1321N1 astrocytoma and A-172 glioblas-
toma as cell models we show that R()WIN 55,212-2, but not its
inactive chiral form S()WIN 55,212-2, strongly inhibits the inter-
leukin-1 (IL-1) induction of the adhesion molecules intercellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion mole-
cule-1 (VCAM-1) and the chemokine IL-8. This inhibition is not
mediated via the CB1 or CB2 cannabinoid receptors, because their
selective antagonists and pertussis toxin failed to affect the inhibi-
tory effects of R()WIN 55,212-2. Furthermore reverse transcrip-
tion-PCR analysis did not detect the expression of either receptor in
1321N1 cells. R()WIN 55,212-2 was shown to inhibit adhesion
molecule and chemokine expression at the level of transcription,
because it strongly inhibited the IL-1 induction of ICAM-1,
VCAM-1, and IL-8 mRNAs and blocked the IL-1 activation of their
promoters. TheNFBpathwaywas then assessed as a lead target for
R()WIN 55,212-2. NFB was measured by expression of a trans-
fected NFB-regulated reporter gene. Using this assay, R()WIN
55,212-2 strongly inhibited IL-1 activation of NFB. Furthermore
R()WIN 55,212-2 inhibited the ability of overexpressed Myd88,
Tak-1, and IKK-2 to induce the reporter gene suggesting that
R()WIN55,212-2 acts at or downstreamof IKK-2 in the IL-1 path-
way. However R()WIN 55,212-2 failed to inhibit IL-1-induced
degradation of IB, excluding IKK-2 as a direct target. In addition
electrophoretic mobility shift and chromatin immunoprecipitation
assays showed that R()WIN 55,212-2 does not regulate the IL-1-
induced nuclear translocation of NFB or the ability of the latter to
bind to promoters regulating expression of ICAM-1 and IL-8. These
data suggest thatR()WIN 55,212-2 blocks IL-1 signaling by inhib-
iting the transactivation potential of NFB.
Inflammation in the CNS2 is a key feature associated with neurode-
generative disorders, including multiple sclerosis (1). Reports have sug-
gested cannabinoids to be of potential therapeutic value in the treat-
ment of such neuro-inflammatory conditions (2–4). More recently two
concurrent reports demonstrated that the synthetic cannabinoid,
R()WIN 55,212-2, ameliorates the progression of clinical disease in a
murine model of multiple sclerosis (5, 6). These studies described anti-
inflammatory activity of R()WIN 55,212-2 in the brain and its ability
to inhibit leukocyte entry into the CNS. This is likely to be a key com-
ponent underlying the therapeutic effects of R()WIN 55,212-2,
because multiple sclerosis is an inflammatory-based disease character-
ized by a strong infiltration of the CNS by leukocytes (7). However, the
molecular basis to the effects of R()WIN 55,212-2 was not addressed
and the potential roles of the two Gi-protein-coupled cannabinoid
receptors (CB1 and CB2) (8) were not resolved. Because R()WIN
55,212-2 has been reported to inhibit the adhesion of leukocytes in the
brain (9), we assessed the regulatory effects ofR()WIN55,212-2 on the
expression of the likely adhesion molecules mediating this adhesion.
Adhesion molecules, such as VCAM-1 and ICAM-1, and chemo-
kines, like IL-8, are elevated in multiple sclerosis lesions and make a
major contribution to the extravasation of leukocytes across the blood-
brain barrier (10–12). Indeed an antibody that blocks the interaction of
leukocytes with VCAM-1 reduces the severity of experimental multiple
sclerosis (13). The expression of adhesionmolecules and chemokines in
multiple sclerosis is prominent in astrocytes (11, 14). We and others
have shown that the pro-inflammatory cytokine IL-1 is a key stimulus in
the induction of VCAM-1, ICAM-1, and IL-8 in astrocytes (15–18).
NFB is a key driver in the induction processes, and IL-1 is a potent
activator of this transcription factor in astrocytes (15, 19). The tran-
scriptional activity of NFB is tightly regulated by its association with
the inhibitory IB that sequestersNFB in the cytosol. IL-1 causes phos-
phorylation of IBproteins by the IB-kinases (IKKs), IKK-1 and IKK-2,
and this leads to IB degradation. This allows for translocation of NFB
to the nucleus, where it activates genes encoding inflammatory proteins,
including adhesionmolecules. One of themost active subunits of NFB
is p65, and the transactivation potential of this subunitmay be enhanced
by phosphorylation at serine residues 276, 529, and 536 (20).
Our study demonstrates that R()WIN 55,212-2 inhibits the IL-1
induction of adhesion molecules, and IL-8 in astrocytes in a manner
independent of CB1 and CB2 receptors. We also show that the likely
mechanism is inhibition of the IL-1-induced transactivation of NFB
without affecting the degradation of IB or the nuclear translocation or
DNA binding of NFB. This increases our molecular understanding of
the anti-inflammatory effects of cannabinoids in the CNS.
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EXPERIMENTAL PROCEDURES
Materials—The human 1321N1 astrocytoma was obtained from the
European Collection of Animal Cell Cultures (Salisbury, UK). The
human A-172 glioblastoma was from American Type Culture Collec-
tion (Manassas, VA). The Epstein-Barr virus-negative human B cell
lymphoma BJAB cell line was a gift from Dr. D. Walls, Dublin City
University, Ireland. Dulbecco’s modified Eagle’s medium, RPMI 1640,
penicillin, streptomycin, fetal calf serum, and Superscript II reverse
transcriptase were from Invitrogen. IL-1 was from NCI, National
Institutes of Health (Frederick,MD). R()WIN 55,212-2 and S()WIN
55,212-2were fromSigma-Aldrich. T4 polynucleotide kinase, the 22-bp
oligonucleotide containing the NFB consensus sequence (underlined)
(5-AGTTGAGGGGACTTTCCCAGGC-3), TaqDNA polymerase,
dNTPs and the Cytotox 96 Non-Radioactive Cytotoxicity Assay were
from Promega Corp. (Madison,WI). RNA ISOLATORwas fromGeno-
sys Biotechnologies, Inc. (Cambridge, UK). SR141716A and SR144528
were gifts from SANOFI-Recherche. Pertussis toxin was from Calbio-
chem-Novabiochem Ltd. Primers and probes for quantitative real-time
PCR analysis of ICAM-1 (Hs00164932_m1), VCAM-1 (Hs00174239_m1),
IL-8 (4309885P), and 18SrRNA (4310893E) were from Applied Biosys-
tems (Foster City, CA). GeneJuice transfection reagent was fromNova-
gen (Madison, WI). The NFB-luciferase reporter plasmid (B-luc)
consists of five copies of the NFB consensus site cloned into the lucif-
erase reporter construct pGL3-Basic (Promega Corp.). The ICAM-1-
luciferase construct consists of 1344 bp of the ICAM-1 upstream region
(1353 to 9 relative to the start of transcription) cloned into the
luciferase reporter vector pGL2 Basic and was a gift from Prof. Luke
O’Neill (Trinity College Dublin, Ireland). The IL-8-luciferase reporter
plasmid was a gift from Dr. Catherine Greene (Beaumont Hospital,
Ireland). The construct encoding IKK-2 was from Tularik (San Fran-
cisco, CA). The construct encoding Tak-1 was a gift from H. Sakurai
(Tanabe Seiyaku, Japan). The Luciferase Assay System with Reporter
Lysis Buffer was from Promega Corp. (Madison, WI). [-32P]ATP was
purchased from Amersham Biosciences. Rabbit polyclonal antibody
against IB- and anti-p65 (sc-372) were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). The antibody against phospho-Ser536 p65
and rabbit IgG was fromCell Signaling Technology (Milton Keynes, UK).
Cell Culture—1321N1 astrocytoma and A-172 glioblastoma were
cultured in Dulbecco’s modified Eagle’s medium supplemented with
100 units/ml penicillin, 100g/ml streptomycin, and 10% (v/v) fetal calf
serum. The cells were passaged using 0.25% (w/v) trypsin in PBS. IL-1
stimulation was performed on cells in serum-containing medium at
37 °C for all experiments. Human BJAB cells were cultured in RPMI
1640 medium supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, 100 units/ml penicillin, and 100 g/ml streptomycin. Cells were
grown in a humidified atmosphere of 5% CO2 at 37 °C.
Enzyme-linked Immunosorbent Assay Detection of Cell Adhesion
Molecules and IL-8—1321N1 astrocytoma andA-172 glioblastoma (4
104 cells/0.2 ml) were plated into 96-well microtiter plates and allowed
to grow for 48 and 24 h, respectively. Cells were pre-treated for desig-
nated times with indicated concentrations of R()WIN 55,212-2,
S()WIN 55,212-2, SR141716A, SR144528, or pertussis toxin prior to
IL-1 (10 ng/ml) treatment for an additional 24 h. Stimulation was
terminated by removal of medium, which was subsequently assayed for
IL-8 using matched antibody pairs (R & D Systems Europe Ltd., Abing-
don, Oxford, UK) in a sandwich enzyme-linked immunosorbent assay
system according to the supplier’s instruction. The adherent cells were
measured for expression of VCAM-1 and ICAM-1 as described previ-
ously (15).
Quantitative Real-time PCR Analysis of Adhesion Molecule and IL-8
Expression—1321N1 astrocytoma (2  105 cells/ml) were plated into
6-well plates and grown for 24 h. Cells were pre-treated for 1 h with
R()WIN 55,212-2 (20 M) prior to IL-1 (10 ng/ml) treatment for an
additional 23 h. Cells were washed once with PBS, and RNA was
extracted usingTri reagent (Sigma). After DNase I digestion, cDNAwas
generated from normalized RNA using SuperScript II reverse tran-
scriptase. Samples were assayed by quantitative real-time PCR for levels
of VCAM-1, ICAM-1, and IL-8 cDNA using the ABI Prism 7900HT
thermal cycler. Reactions were performed using pre-validated primers
and probes (Applied Biosystems).
Assessment of Cytotoxicity Using the CytoTox 96 Non-radioactive
Cytotoxicity Assay—The effect of R()-WIN 55,212-2 on 1321N1 cell
viability was assessed by use of the CytoTox 96 non-radioactive cyto-
toxicity assay (Promega Corp.). This spectrophotometric method is
based on the quantitative measurement of lactate dehydrogenase
(LDH), a stable cytosolic enzyme that is released upon cell lysis, by a
coupled enzymatic assay. 1321N1 astrocytoma (4  104 cells/0.2 ml)
were plated into 96-well microtiter plates and allowed to grow for 48 h.
Cells were then treated with various concentrations of R()WIN
55,212-2 as above. The cell medium was removed and assayed for LDH
activity according to the manufacturer’s instructions, and data were
expressed relative to total LDH activity in the cells. The latter wasmeas-
ured in supernatants from untreated cells previously lysed in Triton
X-100 (1% v/v).
Assay of CB1 and CB2 mRNA Expression—Total cellular RNA was
prepared from 1321N1 astrocytoma and BJAB cells (4 106 cells) using
the RNA ISOLATOR according to the manufacturer’s instructions.
First strand cDNA synthesis was carried out using Superscript II reverse
transcriptase and random oligonucleotide primers, and PCR amplifica-
tion was performed using TaqDNA polymerase and primers to selec-
tively amplify regions of the CB1, CB2, and GAPDH cDNAs. The
sequences of the forward and reverse oligonucleotide primers and the
sizes of the products were: CB1, 5-GAGACAACCCCCAGCTAGTC-
CCAGCAGACC-3 and 5-TGGGCCTGGTGACAATCCTCTTAT-
AGGCC-3, 500 bp; CB2, 5-CTTCTGGCCCTGCTAAGTGCCCTG-
GAGAACG-3 and 5-CAGCAAGTCCATCCCATGAGGGGCAGC-
TAGG-3, 400 bp; and GAPDH, 5-ACCACAGTCCATGCCATC-3
and 5-TCCACCACCCTGTTGCTG-3, 452 bp. Amplification param-
eters were as follows: step 1: 35 cycles at 94 °C for 1 min, at 53 °C for 1
min and at 72 °C for 1min; step 2: at 72 °C for 10min. The PCRproducts
were subjected to electrophoresis on a 1.5% agarose gel, containing
ethidium bromide, and photographed.
Cell Transfections—1321N1 astrocytoma (4 104 cells/0.2 ml) were
plated into 96-well microtiter plates and allowed to grow for 24 h. Cells
were then transfected, using GeneJuice transfection reagent, with des-
ignated firefly luciferase reporter plasmids (80–100 ng), constitutively
expressed Renilla-luciferase reporter construct (phRL-TK) (40 ng), and
expression constructs encoding Myd88, Tak-1, or IKK-2 (80 ng). In
control experiments lacking the latter expression constructs total DNA
was kept constant (240 ng/well) using the pcDNA3.1 empty vector.
Cells were allowed to recover overnight (17 h) and then pre-treatedwith
or without R()WIN 55,212-2 or S()WIN 55,212-2 for 1 h prior to
stimulation in the presence or absence of IL-1 (10 ng/ml) for a further
6 h. Cell extracts were generated using the Reporter lysis buffer (Pro-
mega), and extracts were assayed for firefly luciferase and Renilla-lucif-
erase activity using the Luciferase assay system (Promega) and coelen-
terazine (1 g/ml), respectively.
Preparation of Nuclear and Cytosolic Fractions—1321N1 cells (2 
105 cells/ml; 3 ml) were seeded into 6-well plates and allowed to adhere
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for 72 h. Cells were pre-treated with or without various concentrations
of R()WIN 55,212-2 or S()WIN 55,212-2 for 1 h prior to stimulation
in the presence or absence of IL-1 (10 ng/ml) for 30 min. Stimulation
was terminated by removal of medium, and cells were washed with 5ml
of ice-cold PBS. Cells were then scraped into 1 ml of ice-cold hypotonic
buffer (10 mMHEPES-NaOH buffer, pH 7.9, containing 1.5 mMMgCl2,
10 mM KCl, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl
fluoride). Cells were pelleted by centrifugation at 14,000 g for 10 min
and then lysed for 10 min on ice in hypotonic buffer (20 l) containing
0.1% (v/v) Nonidet P-40. Lysates were centrifuged at 14,000  g for 10
min. The resulting supernatants constituted cytosolic fractions and
were measured for levels of IB by Western immunoblotting as
described previously (19). The pellets were resuspended in 20 mM
HEPES-NaOH buffer, pH 7.9 (15 l), containing 420 mMNaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% (w/v) glycerol, and 0.5 mM phenylmethyl-
sulfonyl fluoride and incubated for 15min on ice. Incubationswere then
centrifuged at 14,000  g for 10 min, and the supernatants were
removed into 10mMHepes/NaOH buffer, pH 7.9 (75l), containing 50
mM KCl, 0.2 mM EDTA, 20% (w/v) glycerol, 0.5 mM phenylmethylsul-
fonyl fluoride, and 0.5 mM dithiothreitol. Such samples constituted
nuclear extracts and were assayed for NFB by the electrophoretic
mobility shift assay.
ElectrophoreticMobility Shift Assay—Nuclear extracts (10g of pro-
tein) were incubated with 30,000 dpm of a 22-bp oligonucleotide con-
taining the NFB consensus sequence, which previously had been
labeled with [-32P]ATP (10 mCi/mmol) by T4 polynucleotide kinase
(19). Incubations were performed for 30min at room temperature in 10
mM Tris-HCl buffer, pH 7.5, containing 100 mM NaCl, 1 mM EDTA, 5
mM dithiothreitol, 4% (w/v) glycerol, 2 g of poly(dI-dC), and 1 mg/ml
nuclease-free bovine serum albumin. All incubations were subjected to
electrophoresis on native 4% (w/v) polyacrylamide gels that were sub-
sequently dried and autoradiographed.
Chromatin Immunoprecipitation and Analysis by Quantitative Real-
time PCR—1321N1 astrocytoma cells were grown to confluency in
90-mm dishes. Cells were pre-treated with or without R()WIN
55,212-2 (20 M) for 1 h prior to stimulation in the absence or presence
of IL-1 (10 ng/ml) for 1 h. ChIP assays were performed as previously
described (21) with some modifications. Following stimulation, cells
were cross-linked with 1% (v/v) formaldehyde for 10 min at 37 °C. Iso-
lated nuclei were subjected to seven 10-s sonication pulses from a
Sanyo/MES Soniprep 150 at one-third of total power. Separate aliquots
from each chromatin preparationwere incubated overnight at 4 °Cwith
FIGURE1.R()WIN55,212-2 inhibits IL-1-inductionof ICAM-1,VCAM-1, and IL-8 in
1321N1 astrocytoma. 1321N1 astrocytoma were pretreated for 1 h with various con-
centrations of the R and S enantiomers ofWIN 55,212-2 and stimulated for a further 24-h
period with IL-1 (10 ng/ml). The cells were then measured for ICAM-1 (a), VCAM-1 (b),
and IL-8 (c) expression by direct and sandwich enzyme-linked immunosorbent assay as
describedunder “Experimental Procedures.” The results are expressed as percentages of
values obtained in IL-1-treated cells in the absence of WIN 55,212-2. d, 1321N1 astro-
cytomawere treatedwith various concentrations of R()WIN 55,212-2 for 24 h and then
assessed for viability bymeasuring LDH release in the conditionedmediumas described
under “Experimental Procedures.” The LDH release is expressed as percentage of total
LDH in the cells. The data represent mean S.E. of three independent experiments.
FIGURE 2. R()WIN 55,212-2 inhibits IL-1 induction of ICAM-1 and IL-8 in A-172
glioblastoma. A-172 glioblastoma were pretreated for 1 h with R()WIN 55,212-2 (20
M) and stimulated for a further 24-h period with IL-1 (10 ng/ml). The cells were then
measured for ICAM-1 (a) and IL-8 (b) expression by direct and sandwich enzyme-linked
immunosorbent assay respectively as described under “Experimental Procedures.” The
ICAM data are expressed as percentages of values obtained in IL-1-treated cells in the
absence of WIN 55,212-2. The data represent mean  S.E. of three independent
experiments.
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anti-p65 antibody and rabbit IgG antibody. An aliquot was also retained
as an input sample to normalize PCR reactions and analyze shearing
efficiency. Chromatin used had an average size of 750 bp. After rever-
sion of cross-links by overnight incubation at 65 °C, DNAwas extracted
using theQIAquick purification kit (Qiagen) according to themanufac-
turer’s instructions. Standard PCR was performed using 1 l (3% of
total) of template DNA, 500 nM primers, and 0.2 unit of TaqDNA
polymerase (Invitrogen) per 50-l reaction. Quantitative real-time PCR
reactionswere performed in duplicatewith 2l of templateDNA, 50 nM
primers, and the SYBR Green Jumpstart Taq Readymix (Sigma), using
the Mx3000P QPCR System (Stratagene). Dissociation curve analysis
and gel electrophoresis of the final products confirmed that only the
expected specific amplicon of correct size was generated for each target
promoter. Real-time PCR data analysis was performed as previously
described (22). Results for each treatment are expressed as -fold differ-
ences between DNA enrichment in the p65-ChIP sample relative to
IgG-ChIP sample. The sequences of primers used are as follows:
ICAM-1, 5-CTCCACTCTCCGGGGAAGTTG-3 and 5-GCTG-
FIGURE 3. R()WIN 55,212-2 inhibits IL-1 induc-
tion of adhesion molecules in a cannabinoid
receptor independentmanner. 1321N1 astrocy-
toma were challenged for 1 h with SR141716A (10
M) (a and b) or SR144528 (10M) (c and d) prior to
treatment with or without R()WIN 55,212-2 (20
M) for 1 h and further stimulation for 24 h with
IL-1 (10 ng/ml). The cells were thenmeasured for
ICAM-1 (a and c) and VCAM-1 (b and d) expression,
and results are expressed as percentages of values
obtained in IL-1-treated cells in the absence of
R()WIN 55,212-2. Thedata representmean S.E.
of three independent experiments.
FIGURE 4. R()WIN 55,212-2 inhibits IL-1 induction of adhesion molecules inde-
pendently of Gi protein. 1321N1 astrocytoma were challenged overnight with pertus-
sis toxin (50 ng/ml) prior to treatment with or without R()WIN 55,212-2 (20 M) for 1 h
and further stimulation for 24 h with IL-1 (10 ng/ml). The cells were thenmeasured for
ICAM-1 (a) and VCAM-1 (b) expression, and results are expressed as percentages of val-
ues obtained in IL-1-treated cells in the absence of R()WIN 55,212-2. The data repre-
sent mean S.E. of three independent experiments.
FIGURE5.LackofexpressionofCB1andCB2receptors in1321N1astrocytoma.Total
cellular RNA was prepared from BJAB and 1321N1 astrocyte cells and subjected to first
strand cDNA synthesis using Superscript II reverse transcriptase and random oligonu-
cleotide primers. PCR amplificationwas performedusing TaqDNApolymerase andprim-
ers to selectively amplify regions of CB1 (a) and CB2 and GAPDH (b) cDNAs. This resulted
in the generation of products with the predicted sizes of 500 bp, 400 bp, and 452 bp,
respectively.
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CAGTTATTTCCGGACTGAC-3; IL-8, 5-GGAAGTGTGATGAC-
TCAGGTTTGC-3 and 5-GATGGTTCCTTCCGGTGGTTTCT-
TC-3; and GAPDH, 5-CTACTAGCGGTTTTACGGGCG-3 and
5-TCGAACAGGAGGAGCAGAGAGCGA-3.
Western Blot Analysis of p65 Phosphorylation—1321N1 astrocytoma
(2  105 cells/ml; 3 ml) were plated into 6-well plates and allowed to
grow for 24 h. Cells were pre-treated with or without R()WIN
55,212-2 for 1 h prior to stimulation in the presence or absence of IL-1
(10 ng/ml) for 30 min. Stimulation was terminated by removal of
medium, and the adherent cells washed with ice-cold PBS (3 ml). The
cells were then scraped into PBS (1ml) and pelleted by centrifugation at
21,000  g for 5 min at 4 °C. The cell pellets were lysed in SDS-PAGE
sample buffer (100 l, 50 mM Tris-HCl buffer, pH 6.8, containing 2%
(w/v) SDS, 10% glycerol, 1% (v/v) 2-mercaptoethanol, and 0.1% brom-
phenol blue). The lysates were sonicated for 10 s to reduce sample
viscosity and then heated to 90 °C for 5 min. Lysates (20 l) were sub-
jected to SDS-PAGE on 10% polyacrylamide slab gels, and the separated
proteins were electrophoretically transferred from the gels to nitrocel-
lulose. The nitrocellulose was then probed for levels of Ser536 phospho-
rylated using specific antibodies as recommended by the manufactur-
ers. Immunoreactivity was visualized by enhanced chemiluminescence.
RESULTS
Because R()WIN 55,212-2 has been reported to inhibit the infiltra-
tion of leukocytes into the brain (9), we initially assessed the regulatory
effects of R()WIN 55,212-2 on the expression of the likely adhesion
molecules and chemokines mediating this infiltration process.We have
previously characterized the ability of IL-1 to induce the expression of
the adhesionmolecules VCAM-1 and ICAM-1 and the chemokine IL-8
in human 1321N1 astrocytoma cells (15, 18), and this was used as the
model in the present study. R()WIN 55,212-2 was assessed for its
ability to inhibit the IL-1 induction of adhesion molecules and IL-8 in
this cell system (Fig. 1). R()WIN 55,212-2 caused a dose-dependent
inhibition of the IL-1 induction of both ICAM-1 (Fig. 1a), VCAM-1
(Fig. 1b), and IL-8 (Fig. 1c) in 1321N1 astrocytoma. The dose-dependent
inhibitory profiles were similar in all three cases. WIN 55,212-2 is avail-
able in two enantiomeric forms, R and S, with R being the active form
(23). In contrast to the R form, the inactive chiral S()WIN 55,212-2
failed to affect the ability of IL-1 to induce ICAM-1 (Fig. 1a) and
VCAM-1 (Fig. 1b) suggesting that a stereoselective mechanism under-
lies the inhibitory effects of R()WIN 55,212-2. To exclude the possi-
bility that the inhibitory effects of R()WIN 55,212-2 were due indi-
rectly to nonspecific cytotoxicity, the viability of the cells after treatment
with the same concentration range of R()WIN 55,212-2 was assessed
by measuring the release of LDH (Fig. 1d). None of the concentrations
of R()WIN 55,212-2 caused any detrimental effects on cellular viabil-
ity indicating that its inhibitory effects on VCAM-1 and ICAM-1
expression are not due to general toxicity.
To ensure that the above effects are not simply artifacts of the 1321N1
astrocytoma cell line, the effect of R()WIN 55,212-2 on A-172 glio-
blastoma, another cell of glia origin, was next examined. Like 1321N1
astrocytoma, A-172 cells showed increased expression of adhesionmol-
ecules such as ICAM-1 (Fig. 2a) and the chemokine IL-8 (Fig. 2b) in
response to IL-1. The pre-treatment of A-172 cells with R()WIN
FIGURE 6.R()WIN55,212-2 inhibits IL-1 inductionofmRNAsencoding ICAM-1 and IL-8 and IL-1 activationof ICAM-1 and IL-8promoters. a and b, 1321N1 astrocytomawere
pre-treated for 1 h with R()WIN 55,212-2 (20 M) prior to IL-1 (10 ng/ml) treatment for an additional 23 h. RNA extracts were generated and converted into cDNA. Samples were
assayed by quantitative real-time PCR for levels of ICAM-1 (a) and IL-8 (b) mRNA using the ABI Prism 7900HT thermal cycler. c and d, 1321N1 cells were co-transfected with ICAM-1
promoter luciferase (100 ng, c), IL-8 promoter luciferase (100 ng, d), phRL-TK (constitutively expressed Renilla luciferase) (40 ng) and pcDNA3.1 (80 ng). Cells were allowed to recover
overnight and thenpre-treatedwith orwithout R()WIN 55,212-2 (20M) for 1 h prior to stimulation in the presence or absence of IL-1 (10 ng/ml) for a further 6 h. Data are expressed
relative to levels in control unstimulated cells (c) and represent mean S.E. of two experiments.
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55,212-2 caused a complete blockade of the IL-1 induction of ICAM-1
(Fig. 2a) and IL-8 (Fig. 2b) thus validating the previous findings from
1321N1 astrocytoma.
The involvement of the cannabinoid receptors CB1 andCB2 inmedi-
ating the inhibitory effects of R()WIN 55,212-2 was next explored by
assessing the ability of the CB1 and CB2 receptor antagonists,
SR141716A and SR144528, respectively, to regulate the inhibitory
effects of R()WIN 55,212-2 in 1321N1 cells. SR141716A had no influ-
ence on the IL-1 induction of ICAM-1 but more importantly failed to
affect the strong inhibitory effects of R()WIN 55,212-2 on the induc-
tion process (Fig. 3a). Similar results were obtained with respect to
VCAM-1 expression (Fig. 3b). This indicates a lack of involvement of
theCB1 receptor inmediating the inhibitory effects. The role of theCB2
receptor was next examined by assessing the regulatory effects of
SR144528 on R()WIN 55,212-2. However, like the CB1 receptor
antagonist, SR144528 failed to regulate the strong inhibitory effects of
R()WIN 55,212-2 on IL-1 induction of ICAM-1 (Fig. 3c) or VCAM-1
(Fig. 3d) in 1321N1 cells and thus tended to exclude a role for the CB2
receptor in mediating the effects of R()WIN 55,212-2.
Because both CB1 and CB2 receptors signal via a Gi protein, and the
latter is subject to inhibition by pertussis toxin, the roles of CB1 andCB2
receptors were further probed by investigating the regulation of the
effects of R()WIN 55,212-2 by this toxin. However the inability of
pertussis toxin to modulate the inhibitory effects of R()WIN 55,212-2
FIGURE 7.R()WIN55,212-2 inhibits IL-1 inductionofNFB-regulated reporter gene in 1321N1astrocytoma. a and b, 1321N1 cells were co-transfectedwith aNFB-regulated
firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed Renilla luciferase) (80 ng), and pcDNA3.1 (80 ng). Cells were allowed to recover overnight and then pre-treated
with or without various concentrations of R()WIN 55,212-2 (a) or S()WIN 55,212-2 (b) for 1 h prior to stimulation in the presence or absence of IL-1 (10 ng/ml) for a further 6 h. c–e,
1321N1 cells were co-transfected with a NFB-regulated firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed Renilla luciferase) (80 ng), and pcDNA3.1 (80 ng) or
expression plasmids encodingMyd88 (c), Tak-1 (d), or IKK-2 (e) (80 ng). Cellswere allowed to recover overnight and then treatedwith orwithout R()WIN 55,212-2 (20M) for 7 h. Cell
extracts were generated and assayed for firefly and Renilla (for normalizing transfection efficiency) luciferase. Data are presented as normalized firefly luciferase activity.
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on IL-1 induction of ICAM-1 (Fig. 4a) or VCAM-1 (Fig. 4b) further
confirms the lack of involvement of the CB1 andCB2 receptors inmedi-
ating the responses to R()WIN 55,212-2.
The above findings prompted an analysis of the expression levels of
the two receptors in 1321N1 astrocytoma. The highly sensitive
approach of RT-PCR was exploited to amplify the CB1 and CB2 recep-
tors by using primers that specifically amplify regions of the CB1 or CB2
receptor cDNAs. The BJAB cell line was also probed for expression of
both receptor subtypes and acted as a positive control for the primers
and RT-PCR procedure, since it has previously been shown that B cells
express high levels of cannabinoid receptors (24). Indeed the RT-PCR
analysis in the present study resulted in the generation of products with
the predicted sizes of 500 bp (CB1) and 400 bp (CB2) in BJAB cells (Fig.
5a) demonstrating that these cells express both CB1 and CB2. In addi-
tion the generation of these products validates the primers and PCR
conditions as a suitable detection system for the expression of both
receptors. Intriguingly, the equivalent RT-PCR analysis of RNA from
1321N1 astrocytoma failed to generate any such products indicating
that these cells do not express the CB1 and CB2 receptors (Fig. 5a). To
confirm the RNA from 1321N1 cells as a suitable source for RT-PCR
analysis, primers were also used to amplify a region of the housekeeping
GAPDHgene (Fig. 5b). This resulted in the generation of a PCR product
of the predicted 452-bp sizewith BJAB and 1321N1 cells both displaying
comparable levels of the product. This indicates the absence of expres-
sion of CB1 and CB2 receptors in 1321N1 astrocytoma and unambigu-
ously confirms that the inhibitory effects of R()WIN 55,212-2 on
adhesion molecule and chemokines expression in glial cells are medi-
ated by a mechanism independent of these receptors.
In an effort to delineate the mechanism underlying the inhibitory
effects of R()WIN 55,212-2, transcriptional regulation of adhesion
molecule and chemokine expression by IL-1 was probed as a potential
target for R()WIN 55,212-2. Real-time PCR was used to quantitate
levels of mRNA encoding ICAM-1, VCAM-1, and IL-8. IL-1 caused
over 100-fold induction of ICAM-1mRNA in 1321N1 cells, and this was
blocked by pre-treatment with R()WIN 55,212-2 (Fig. 6a). Similarly
IL-1 caused robust induction of IL-8mRNA in these cells, and again this
was inhibited byR()WIN55,212-2 (Fig. 6b). IL-1 also strongly induced
VCAM-1 mRNA in 1321N1 cells, but because this mRNA species was
undetectable in untreated cells it was not possible to express -fold
induction by IL-1. It is worth noting, however, that R()WIN 55,212-2
inhibited, by 80%, the induction of VCAM-1 by IL-1 (data not shown).
To further characterize the inhibitory effects of R()WIN 55,212-2 on
the transcription of ICAM-1 and IL-8, its effects on the IL-1 activation
of ICAM-1 and IL-8 promoters were explored. IL-1 caused induction of
luciferase that is regulated by the ICAM-1 promoter, and this was
blocked by R()WIN 55,212-2 (Fig. 6c). IL-1 caused even stronger
induction of luciferase that is regulated by the IL-8 promoter, and again
this was inhibited by R()WIN 55,212-2 (Fig. 6d).
The inhibitory effects of R()WIN 55,212-2 on the IL-1 activation of
the ICAM-1 and IL-8 promoters and the ensuing blockade of IL-1
induced transcription of ICAM-1 and IL-8 suggested that transcription
factors regulating these promoters may be key targets for R()WIN
55,212-2. The crucial role of NFB in IL-1 signaling coupled to its reg-
ulation of adhesion molecule and chemokine expression in astrocytes
(15, 18) promoted it as a lead candidate.R()WIN 55,212-2was initially
examined for its effects on IL-1 induction of a NFB-regulated reporter
gene. R()WIN 55,212-2 caused a strong and dose-dependent inhibi-
tion of the IL-1 induction of the reporter gene (Fig. 7a), whereas its
chiral form S()WIN 55,212-2 was ineffective (Fig. 7b). In an effort to
further resolve the point of the IL-1 pathway that is subject to inhibition
by R()WIN 55,212-2, the sensitivity of a number of signaling mole-
cules at various stages in the IL-1 pathway was examined. ThusMyd88,
Tak-1, and IKK-2were overexpressed and shown to cause robust induc-
tion of the NFB-regulated reporter gene (Fig. 7, c–e). Interestingly
R()WIN 55,212-2 strongly inhibited the ability of each of the signaling
molecules to induce the reporter gene suggesting that it targets the IL-1
pathway at or downstream of IKK-2.
Because IKK-2 directly phosphorylates the IB proteins leading to
their degradation, IKK-2 was assessed as a target by probing the effects
of R()WIN 55,212-2 on IL-1-induced degradation of IB. IL-1
caused complete degradation of IB after 30 min, but neither
R()WIN 55,212-2 nor its chiral S form inhibited this degradation
indicating that the IKKs are not direct targets for R()WIN 55,212-2
(Fig. 8a).
The degradation of IB is followed by nuclear translocation of NFB
and its subsequent binding to DNA motifs in specific promoters. Thus
these steps were also examined as potential targets for R()WIN
55,212-2. This was initially performed by generating nuclear extracts
and measuring for binding to oligonucleotides containing the consen-
sus NFB motif by the electrophoretic mobility shift assay. IL-1 caused
the strong activation of NFB in this assay as judged by the increased
intensity of the retarded NFBDNA complexes in IL-1-treated cells
(Fig. 8b). Pre-treatment with either form of WIN 55,212-2 failed to
affect this activation suggesting that R()WIN 55,212-2 does not target
the nuclear translocation or DNA-binding capacity of NFB.
More specific studies were performed to characterize the effects of
R()WIN 55,212-2 on the specific binding of NFB to the ICAM-1 and
IL-8 promoters. Because the in vivo binding of transcription factors to
DNA occurs within the context of intact chromatin structures, ChIP
assays were performed to evaluate whether R()WIN 55,212-2 could
affect the binding of the NFB subunit, p65, to the ICAM-1 and IL-8
promoters. p65 was absent at the promoters in unstimulated 1321N1
cells, but after 1-h stimulation with IL-1, p65 was detected at both pro-
moters (Fig. 9a). This IL-1-induced promoter binding was not affected
FIGURE 8. R()WIN 55,212-2 does not regulate IL-1-induced degradation of IB,
nuclear translocation, orDNAbindingofNFB.1321N1astrocytomawerepretreated
for 1 h with various concentrations of the R and S enantiomers of WIN 55,212-2 and
stimulated for a further 30minwith IL-1 (10 ng/ml). a, cytosolic extracts were prepared
and analyzed by Western immunoblotting for levels of I. b, nuclear extracts were
prepared and assessed for NFB activity by electrophoretic mobility shift assay.
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by pre-treatment with R()WIN 55,212-2. This was confirmed by
quantitative real-time PCR analysis of the immunoprecipitated chro-
matin (Fig. 9b). One-way analysis of variance indicated that induction of
p65 binding to both promoters by IL-1 was statistically significant in the
absence or presence of R()WIN 55,212-2 pre-treatment, and there
was no significant difference in the binding induced by IL-1 between
these conditions. These findings suggest that R()WIN 55,212-2 does
not interfere with the binding of NFB to its promoters and must
instead target the later stage of transactivation by NFB.
We have previously shown that the only transactivating subunit of
NFB that is activated by IL-1 in 1321N1 cells is p65 (18). Because the
activity of p65 is subject to regulation by phosphorylation at serine
residues 276, 529, and 536, we sought to examine the potential regula-
tion of phosphorylation of these sites by 276, 529, and 536 by R()WIN
55,212-2. Preliminary studies with phospho-specific antibodies failed to
detect phosphorylation of residues 276 and 529 in response to IL-1 (data
not shown) and thus these sites were not further explored. However
using an antibody that specifically detects modified p65, which is phos-
phorylated at residue 536, it was possible to show that IL-1 caused
increased phosphorylation at this site (Fig. 10). However the pre-treat-
ment of cells with R()WIN 55,212-2 failed to affect this phosphoryla-
tion suggesting that it inhibits the transactivation of NFB by a novel
mechanism.
DISCUSSION
Cannabinoids exert many different effects in the brain, but much
interest has recently focused on their neuroprotective value, and their
promising potential as agents to treat neurological disorders such as
multiple sclerosis. The aminoalkylindole R()WIN 55,212-2 is of spe-
cial interest due its impressive therapeutic effects in ameliorating dis-
ease progression in animal models of multiple sclerosis (5, 6). Although
the latter studies showed that R()WIN 55,212-2 inhibits leukocyte
entry into the CNS and reduces the expression of pro-inflammatory
cytokines the molecular mechanism underlying its effects was not
addressed. In the present study we show that R()WIN 55,212-2
strongly inhibits the expression of the adhesionmoleculesVCAM-1 and
ICAM-1 and the chemokine IL-8 in astrocytes. The reduced expression
of adhesion molecules in astrocytes is likely to play a key role in medi-
FIGURE9.R()WIN55,212-2doesnot inhibit IL-1-inducedbindingofp65 to ICAM-1or IL-8promoters.1321N1astrocytomawerepre-treatedwithorwithoutR()WIN55,212-2
(20 M) for 1 h prior to stimulation for a further 1 h in the absence or presence of IL-1 (10 ng/ml). Chromatin immunoprecipitations were performed using anti-p65 or control IgG
antibodies andDNA analyzed for ICAM-1, IL-8, andGAPDHpromoters by PCR and gel electrophoresis (a) and quantitative real-time PCR (b). Data from real-time PCR are expressed as
-fold differences between DNA enrichment in the anti-p65-ChIP sample relative to IgG-ChIP sample and are displayed as mean S.E. from two independent experiments. These
values were analyzed by one-way analysis of variance to determine statistical significance between treatments. *, a value statistically significant (p 0.05) from the control value in
untreated cells (c).
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ating the therapeutic effects of R()WIN 55,212-2, because in acute
multiple sclerosis lesions these adhesion molecules are strongly
expressed in astrocytes (10), and strategies that interfere with their
adhesive function inhibit leukocyte-astrocyte interactions (25) and
reduce the severity of experimentalmultiple sclerosis (13). Furthermore
the concentrations of R()WIN 55,212-2 that are required for mani-
festing inhibitory effects in the present study are comparable with the
therapeutic doses used in the animal studies. In addition we found the
chiral form S()WIN 55,212-2 to be inactive and this is consistent with
its lack of effect in the animal models (5), thus further validating our
experimental model.
Three independent approaches unambiguously dictate that the
effects of R()WIN 55,212-2, with respect to inhibition of adhesion
molecule expression in 1321N1 astrocytoma, are mediated by a mech-
anism independent of the CB1 and CB2 receptors. Firstly, selective
antagonists for these receptors fail to influence the effects of R()WIN
55,212-2. Secondly, both receptors are coupled to a Gi protein and yet
pertussis toxin, an inhibitor of this protein, has no effect on R()WIN
55,212-2. Lastly, the highly sensitive approach of RT-PCR failed to
detect expression of either receptor in 1321N1 cells. Indeed the lack of
expression of either receptor in the astrocytoma cells is consistent with
previous reports showing their absence in primary astrocytes (26, 27).
The non-polar nature of R()WIN 55,212-2 raises the possibility that
its effects may be mediated via a nonspecific membrane-acting effect.
However, this is highly unlikely on the basis of the stereoselectivity of
the response to WIN 55,212-2. Indeed this work suggests the likely
involvement of a novel receptor in mediating the inhibitory effects of
R()WIN 55,212-2 in astrocytes.
R()WIN 55,212-2 exerted strong inhibitory effects on the IL-1-in-
duced activation of the ICAM-1 and IL-8 promoters resulting in block-
ade of IL-1 induction of mRNAs encoding ICAM-1 and IL-8. This
strongly suggests that R()WIN 55,212-2 inhibits the expression of
such genes by targeting the transcription process or the upstream path-
ways that promote transcription. The NFB pathway was chosen as a
lead candidate target for R()WIN 55,212-2 due to its indispensable
role in driving expression of pro-inflammatory proteins. R()WIN
55,212-2 caused strong inhibition of NFB at the level of transactiva-
tion, because it inhibited the expression of a NFB-regulated reporter
gene but failed to affect the IL-1-induced degradation of IB and the
nuclear translocation andDNAbinding activity of NFB. This was con-
firmed in ChIP assays by the lack of effect of R()WIN 55,212-2 on the
in vivo binding of the NFB subunit p65 to the ICAM-1 and IL-8 pro-
moters. In the ChIP studies, p65 was chosen as the target Rel subunit for
a number of reasons. Firstly, it possesses transactivating ability (28).
Secondly, the predominant form of NFB activated by IL-1 in 1321N1
astrocytoma cells is the p65/p50 heterodimer (19). Furthermore studies
have shown that the formofNFB,which binds to the variantB sites in
both the ICAM-1 and IL-8 promoters, is the p65 homodimer (29, 30).
Although flanking elements in the promoters of these genes can influ-
ence the level of transcriptional activation, binding of p65 is an essential
step in the IL-1-mediated induction of gene expression.
The mechanism by which R()WIN 55,212-2 targets NFB remains
to be resolved. The present studies suggest thatR()WIN55,212-2 does
not regulate the phosphorylation of the p65 subunit at sites associated
with regulation of transactivation. Indeed serine 536 was the only resi-
due that we could show to be phosphorylated in response to IL-1, and
this was not affected by R()WIN 55,212-2. This is hardly surprising,
because IKK-2 has been proposed as the likely kinase responsible for
phosphorylation of serine 536 and the lack of effect of R()WIN
55,212-2 on IL-1-induced degradation of IB strongly suggests that
IKK-2 is not a target for R()WIN 55,212-2. The targeting of transac-
tivation of NFB by R()WIN 55,212-2 differs significantly from the
endocannabinoid anandamide that has been shown in T lymphocytes
and adenocarcinoma cells to inhibit tumor necrosis factor activation of
NFB by targeting IKK-2 and blocking IB degradation (31). This raises
the interesting notion that R()WIN 55,212-2 may exert at least some
of its effects by a mechanism that differs from the endocannabinoids.
The inhibitory effect of R()WIN 55,212-2 on NFB transactivation
is likely to be the key contributor to its ability to block IL-1 induction of
adhesionmolecule and chemokines expression in astrocytes and reduce
leukocyte entry into the CNS. In addition the therapeutic effects of
R()WIN 55,212-2 in a viral model of multiple sclerosis are associated
with decreased transcription of the pro-inflammatory cytokines tumor
necrosis factor, IL-1 and IL-6 that are strongly controlled by NFB (5).
The targeting of NFB by R()WIN 55,212-2, as shown in the present
study, is likely to be a key mechanism leading to the reduced expression
of these pro-inflammatory cytokines.
The inhibition of the IL-1 signaling pathway by R()WIN 55,212-2 is
also likely to be a key factor in manifesting the therapeutic effects of the
latter in neuropathology. IL-1 has been shown to be a key regulator of
neuro-inflammation and cell death in neurodegenerative conditions
(32, 33). Interestingly, a recent report has shown that the anti-inflam-
matory and neuroprotective actions of cannabinoids in brain cells are
mediated by the induction of the IL-1-receptor antagonist (34). The
present study raises the intriguing concept that cannabinoidsmay target
the IL-1 pathway not only by induction of an endogenous receptor
antagonist but also by inhibition of the downstream signaling cascade.
In summary, the present study probes the molecular basis to the
anti-inflammatory and therapeutic effects of cannabinoids in multiple
sclerosis. It is proposed that the synthetic cannabinoid R()WIN
55,212-2 may produce anti-inflammatory effects by inhibiting NFB,
most likely at the level of transactivation. This increases our molecular
appreciation of the potential use of cannabinoids in the treatment of
neuropathological conditions.
REFERENCES
1. Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B., Comi, G., and Filippi,
A. (2002) Lancet Neurol. 1, 499–509
2. Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G.W., andMyers, L.W. (1987)
Adv. Alcohol Subst. Abuse 7, 39–50
3. Consroe, P., Musty, R., Rein, J., Tillery, W., and Pertwee, R. (1997) Eur. Neurol. 38,
44–48
4. Meinck, H. M., Schonle, P. W., and Conrad, B. (1989) J. Neurol. 236, 120–122
5. Croxford, J. L., and Miller, S. D. (2003) J. Clin. Invest. 111, 1231–1240
6. Arevalo-Martin, A., Vela, J. M., Molina-Holgado, E., Borrell, J., and Guaza, C. (2003)
J. Neurosci. 23, 2511–2516
7. Hafler, D. A., and Weiner, H. L. (1987) Immunol. Rev. 100, 307–332
8. Slipetz, D. M., O’Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay,
FIGURE 10. R()WIN 55,212-2 does not regulate IL-1-induced phosphorylation of
p65 at serine residue 536. 1321N1 astrocytoma were pretreated for 1 h with R()WIN
55,212-2 (50 M) and stimulated for a further 30 min with IL-1 (10 ng/ml). Whole cell
lysates were prepared and analyzed byWestern immunoblotting for levels of p65 phos-
phorylated at residue 536 using an antibody that specifically reacts with this phospho-
rylated form of p65.
R()WIN 55,212-2 Inhibits Interleukin-1 Signaling
OCTOBER 28, 2005•VOLUME 280•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 35805
 at M
aynooth U
niversity on June 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
D., Labelle, M., and Metters, K. M. (1995)Mol. Pharmacol. 48, 352–361
9. Ni, X., Geller, E. B., Eppihimer, M. J., Eisenstein, T. K., Adler, M.W., and Tuma, R. F.
(2004)Mult. Scler. 10, 158–164
10. Brosnan, C. F., Cannella, B., Battistini, L., and Raine, C. S. (1995) Neurology 45,
S16–S21
11. Cannella, B., and Raine, C. S. (1995) Ann. Neurol. 37, 424–435
12. Hesselgesser, J., and Horuk, R. (1999) J. Neurovirol. 5, 13–26
13. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., and Karin,
N. (1992) Nature 356, 63–66
14. Kwon, D., Fuller, A. C., Palma, J. P., Choi, I. H., and Kim, B. S. (2004)Glia 45, 287–296
15. Moynagh, P.N.,Williams,D.C., andO’Neill, L. A. (1994) J. Immunol.153, 2681–2690
16. Rosenman, S. J., Shrikant, P., Dubb, L., Benveniste, E. N., and Ransohoff, R. M. (1995)
J. Immunol. 154, 1888–1899
17. Shrikant, P., Chung, I. Y., Ballestas, M. E., and Benveniste, E. N. (1994) J Neuroimmu-
nology 51, 209–220
18. Bourke, E., and Moynagh, P. N. (1999) J. Immunol. 163, 2113–2119
19. Bourke, E., Kennedy, E. J., and Moynagh, P. N. (2000) J. Biol. Chem. 275,
39996–40002
20. Schmitz, M. L., Bacher, S., and Kracht, M. (2001) Trends Biochem. Sci. 26, 186–190
21. Saccani, S., Pantano, S., and Natoli, G. (2002) Nat. Immunol. 3, 69–75
22. Chakrabarti, S. K., James, J. C., and Mirmira, R. G. (2002) J. Biol. Chem. 277,
13286–13293
23. Herzberg, U., Eliav, E., Bennett, G. J., and Kopin, I. J. (1997) Neurosci. Lett. 221,
157–160
24. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P.,
Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P. (1995) Eur. J. Biochem. 232,
54–61
25. Hery, C., Sebire, G., Peudenier, S., and Tardieu, M. (1995) J. Neuroimmunol. 57,
101–109
26. Sagan, S., Venance, L., Torrens, Y., Cordier, J., Glowinski, J., and Giaume, C. (1999)
Eur. J. Neurosci. 11, 691–699
27. Walter, L., and Stella, N. (2003) Glia 44, 85–90
28. Moore, P. A., Ruben, S. M., and Rosen, C. A. (1993)Mol. Cell. Biol. 13, 1666–1674
29. Ledebur, H. C., and Parks, T. P. (1995) J. Biol. Chem. 270, 933–943
30. Kunsch, C., Lang, R. K., Rosen, C. A., and Shannon, M. F. (1994) J. Immunol. 153,
153–164
31. Sancho, R., Calzado, M. A., Di Marzo, V., Appendino, G., and Munoz, E. (2003)Mol.
Pharmacol. 63, 429–438
32. Rothwell, N. J., and Luheshi, G. N. (2000) Trends Neurosci. 23, 618–625
33. Basu, A., Krady, J. K., and Levison, S. W. (2004) J. Neurosci. Res. 78, 151–156
34. Molina-Holgado, F., Pinteaux, E., Moore, J. D., Molina-Holgado, E., Guaza, C., Gib-
son, R. M., and Rothwell, N. J. (2003) J. Neurosci. 23, 6470–6474
R()WIN 55,212-2 Inhibits Interleukin-1 Signaling
35806 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 43•OCTOBER 28, 2005
 at M
aynooth U
niversity on June 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Fitzgerald and Paul N. Moynagh
Niamh M. Curran, Bryan D. Griffin, Daniel O'Toole, Kevin J. Brady, Stephen N.
Pathway in Human Astrocytes in a Cannabinoid Receptor-independent Manner
(+)WIN 55,212-2 Inhibits the Interleukin-1 SignalingRThe Synthetic Cannabinoid 
doi: 10.1074/jbc.M507959200 originally published online August 16, 2005
2005, 280:35797-35806.J. Biol. Chem. 
  
 10.1074/jbc.M507959200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/280/43/35797.full.html#ref-list-1
This article cites 34 references, 14 of which can be accessed free at
 at M
aynooth U
niversity on June 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
